Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Leukemia & lymphoma·2026
Same author

Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.

Blood advances·2026
Same author

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Blood neoplasia·2026
Same author

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

NEJM evidence·2026
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Related Experiment Video

Updated: Jul 30, 2025

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K

Updates in Risk Stratification in Myelodysplastic Syndromes.

Luis E Aguirre1, David A Sallman, Richard Stone

  • 1From the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Cancer Journal (Sudbury, Mass.)
|May 17, 2023
PubMed
Summary
This summary is machine-generated.

The Molecular International Prognostic Scoring System refines myelodysplastic syndromes risk stratification. It integrates molecular data with traditional factors for improved treatment planning and clinical trial design.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Jul 30, 2025

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Risk stratification is crucial for myelodysplastic syndromes (MDS) treatment planning.
  • Traditional models like the International Prognostic Scoring System (IPSS) use clinical and cytogenetic data.
  • These models have limitations in capturing the full prognostic complexity of MDS.

Purpose of the Study:

  • To introduce the Molecular International Prognostic Scoring System (MIPSS) as an advanced risk stratification tool for MDS.
  • To integrate molecular data into risk assessment for MDS.
  • To improve the accuracy of prognostic models in MDS.

Main Methods:

  • Development of the MIPSS by incorporating molecular markers alongside clinical and cytogenetic data.
  • Utilizing advancements in DNA sequencing to identify relevant mutations.
  • Comparative analysis with traditional IPSS models.

Main Results:

  • The MIPSS provides a more refined prognostic assessment compared to older models.
  • Integration of molecular data enhances the predictive accuracy for MDS patient outcomes.
  • Identified specific mutations with diagnostic and therapeutic relevance.

Conclusions:

  • The MIPSS represents a significant advancement in MDS risk stratification.
  • Molecular profiling is essential for comprehensive MDS prognostication.
  • This novel model can optimize treatment planning and clinical trial strategies for MDS.